Items Tagged with 'Daily International Pharma Alert'

Kenya is the latest country to assert that it will not let international patent protection restrict access to life-saving medicines, including HIV drugs, according to a report from the U.N. Integrated Regional Information Networks (IRIN).

The FDA's Arthritis Advisory Committee voted 20-1 against recommending approval of Merck's Arcoxia, a potential successor to Vioxx as a treatment for arthritis pain.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a public consultation on whether naproxen 250-mg tablets should be made available OTC for treating primary dysmenorrhoea, or period pain, for women ages 15 to 50.

A new drug for treating attention-deficit/hyperactivity disorder (ADHD) will be listed on Australia's Pharmaceutical Benefits Scheme (PBS) starting July 1, the Ministry of Health and Ageing announced.

A weeklong meeting of African Union (AU) health ministers is under way in Johannesburg, South Africa, and activists have expressed concern that commitments on HIV/AIDS made at meetings last year are missing from the agenda, the U.N. Integrated Regional Information Networks (IRIN) reports.

AstraZeneca is suing Novartis subsidiary Sandoz to block it from marketing generic Seroquel, documents filed in U.S. federal court last week revealed.

Gilead Sciences is planning to invest 60 million euros in developing a new world-class pharmaceutical plant in Dublin, Ireland, the country's Minister for Enterprise, Trade and Employment Micheál Martin announced.

In response to the U.S government's request for a World Trade Organization panel to investigate intellectual property rights enforcement in China, the Pharmaceutical Research and Manufacturers of America (PhRMA) issued a statement saying the move shows the U.S. government's commitment to fighting counterfeit drugs.

This week, the African Union (AU) is holding a Conference of Ministers of Health in Johannesburg, South Africa, to discuss strengthening the continent's health systems.

Abbott Laboratories' new Barceloneta, Puerto Rico, manufacturing facility will be the primary production facility for the TNF inhibitor Humira, the firm announced.